Loading stock data…
ABBV
$225.42+2.35 (+1.05%)
After Hours$225.22-0.20 (-0.09%)· Last close Jun 9
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AbbVie Inc. in the Healthcare sector is trading at $225.42 with a market capitalization of $380.6B. Wall Street consensus targets $253.55 (29 analysts), implying a +12.5% move over the next 12 months. The stock is currently 8% below its 52-week high of $244.81, remaining 3.7% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +12.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$225.42
Potential Downside
69.6%
Whystock Fair Value$68.58
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus29 analysts
Buy
Mean target$253.55+12.5%
Range$184.00 – $328.00
Fundamentals
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$380.57B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
105.07
Beta
Defensive asset. Lower volatility than the S&P 500.
0.30
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.99%
ROE
Average efficiency. Growth may require heavy reinvestment.
-89.91%
Volume
Today's trading volume
4.06M
Recent News
Why Is Lilly Stock Growing Like A Silicon Valley Tech Darling?
More than a simple climb, the drugmaker's stock re-rated on a growth story that somehow keeps getting bigger.
3 Stocks That May Be Priced Below Their Estimated Value In June 2026
Over the last 7 days, the United States market has dropped 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this environment, identifying stocks that may be priced below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth prospects.
The Dividend Growth Portfolio That Starts at $40,000 a Year and Ends at $150,000
A retiree’s $40,000 dividend income stream sounds modest next to a neighbor’s $90,000. But the growth rate often matters more than the starting number. A portfolio generating $40,000 today that grows its income by 8% annually produces roughly $86,000 in ten years and more than $186,000 in twenty. That is the power of compounding. The ... The Dividend Growth Portfolio That Starts at $40,000 a Year and Ends at $150,000
Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month?
ABBV climbs 12% a month as investors weigh the raised 2026 guidance, Skyrizi and Rinvoq growth, and multiple pipeline updates.
Can MariTide Save Amgen Stock From Its Fading Blockbusters?
The biotech giant is bucking the market trend, but its real value for investors lies in a story that unfolds over years, not days.